Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC)

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

EP. 1: Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

June 25th 2024

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

EP. 2: Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

June 25th 2024

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

EP. 3: Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

July 12th 2024

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

EP. 4: Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

July 12th 2024

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

EP. 5: Management of Borderline Resectable NSCLC

August 8th 2024

The panel discusses reassessing for respectability after certain treatments.

EP. 6: Management of Resectable Early Stage NSCLC with Actionable Mutations

August 8th 2024

The panel discusses management of resectable early-stage non–small cell lung cancer.

EP. 7: Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

August 8th 2024

The panel discusses the factors that go into selecting patients for adjuvant therapy.

EP. 8: Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

August 8th 2024

The panel looks at a second patient case study.

EP. 9: Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

August 8th 2024

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

EP. 10: Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

August 8th 2024

The panel discusses treatment considerations for consolidation durvalumab.